Medical Devices

After a tense battle with delisting threats, medical technology firm Lifeward has secured its Nasdaq status, clearing the way to refocus on its mission.

A new study validates Noah Medical's robotic bronchoscopy, showing near-perfect accuracy in diagnosing hard-to-reach lung nodules.

As the aesthetics industry booms, a new fractional CFO service aims to solve the growing financial pains and margin crisis facing practice owners.

With a key clinical trial complete, Emboline's new funding aims to commercialize a device designed to make popular heart procedures safer for patients.

Dr. Yulun Wang, inventor of the first FDA-approved surgical robot, joins AiM Medical Robotics, signaling a major leap forward for MRI-guided brain surgery.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

A new study reveals prior authorization policies cause critical delays for heart failure drugs, disproportionately harming vulnerable groups and raising safety concerns.

As automation demand soars, ATS Corp. will meet investors to outline its strategy for navigating market shifts and capitalizing on life sciences growth.

Amid mixed results, Kimball Electronics heads to key investor conferences with a new growth story fueled by medical tech and a raised financial outlook.

With a strong cash position and new leadership, Artiva pivots its AlloNK® cell therapy to autoimmune disease, targeting a pivotal trial for RA in 2026.

Dallas Nephrology Associates earns its second Burl Osborne Award, a testament to its sustained, innovative commitment to fighting kidney disease in Texas.

A new fellowship at the Institut Pasteur aims to revolutionize public health by training scientists in what its founder calls the '3Ms': Money, Management, and Medicine.

A leading Idaho dental group is up for sale, highlighting the growing trend of private equity investment and consolidation in local healthcare services.

The xIoT security firm is a finalist for Best Vulnerability Management Solution, while its CEO is up for Security Executive of the Year.

An Alabama firm's key regulatory filing for a critical drug component could accelerate the development of cheaper cancer supportive care biosimilars.

PainTEQ's landmark deal, crowned 'Deal of the Year,' showcases a new model for medtech growth and its patient-first mission in pain management.

New analysis of Phase 1 data for NKGen Biotech’s troculeucel suggests cognitive benefits, offering a potential new weapon against neuroinflammation.

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.